Mumbai, January 15, 2026: Mangalam Drugs and Organics Limited posted a sharp deterioration in its consolidated financial performance for the quarter and nine months ended December 31, 2025, as lower operating income and sustained cost pressures pushed the company into deeper losses.
Q3 FY26 Performance Snapshot
For the December 2025 quarter, total income from operations declined to ₹5,848.75 lakh, compared with ₹8,871.20 lakh in the same quarter last year. Net sales stood at ₹5,837.64 lakh, significantly lower than ₹8,855.29 lakh reported a year ago.Total expenses during the quarter increased to ₹6,438.02 lakh, led by higher material consumption, employee benefit expenses, and other operating costs. This resulted in a loss from operations before finance costs of ₹578.19 lakh, compared with a profit of ₹485.54 lakh in Q3 FY25.
After accounting for finance costs of ₹405.31 lakh, the company reported a loss before tax of ₹983.50 lakh, reversing a profit before tax of ₹136.68 lakh in the year-ago quarter.
Net Loss and EPS
Mangalam Drugs reported a net loss of ₹983.55 lakh for Q3 FY26, compared with a net profit of ₹128.68 lakh in Q3 FY25.Basic earnings per share for the quarter stood at ₹-6.21, against ₹0.81 in the corresponding quarter last year.
Nine-Month Performance
For the nine months ended December 31, 2025, total income from operations fell to ₹16,538.03 lakh, from ₹24,519.16 lakh in the corresponding period of the previous year.Total expenses rose to ₹18,769.34 lakh, resulting in a loss before tax of ₹3,530.00 lakh, compared with a profit before tax of ₹315.13 lakh in the same period last year.
After tax, the company reported a net loss of ₹3,098.01 lakh for the nine-month period, against a net profit of ₹666.13 lakh a year ago. Basic EPS for the nine months stood at ₹-19.57, compared with ₹4.21 in the previous year period.
Cost and Finance Overview
Finance costs for the nine-month period increased to ₹1,312.59 lakh, up from ₹1,090.25 lakh last year, continuing to weigh on profitability. Employee benefit expenses stood at ₹2,530.01 lakh, while other expenses remained elevated, reflecting a challenging cost environment.Balance Sheet and Capital
The company’s paid-up equity share capital remained unchanged at ₹1,582.82 lakh, with a face value of ₹10 per share.About the Company
Mangalam Drugs and Organics Limited is engaged in the manufacture of active pharmaceutical ingredients and specialty chemicals, catering to domestic and export markets. The company is listed on Indian stock exchanges and operates manufacturing facilities serving pharmaceutical and chemical customers across multiple regions.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.